Macrophage Therapeutics
Englewood Cliffs
About Macrophage Therapeutics
Macrophage Therapeutics (MT) is developing novel immuno-oncology and targeted anti-inflammatory therapeutics based on its proprietary Activated Macrophage targeting platform. MT is leveraging its unique CD206 receptor-based delivery system to deliver proven therapeutics in a more precise and targeted fashion. With binding affinities 10,000X today’s best antibodies MT’s approach eliminates off-target toxicity and increases the efficacy of proven therapeutic agents. MT’s CD206 targeting platform is already clinically established and being used in an FDA/EMEA approved radiopharmaceutical.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.5M
- Funding stage: Seed
- Last round: Seed (Mar 2015)
- Website: macrophagetherapeutics.com
- Phone: [email protected]
Industries & Categories
Oncology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/macrophage-therapeutics-2425017 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.